Moraxella Catarrhalis Lipooligosaccharide Based Conjugate Vaccines for the Prevention of Otitis Media and Respiratory Infections

Moraxella catarrhalis is one of the three leading causative agents of otitis media in children. This is due in part to the current immunizations of children with Streptococcus pneumoniae polysaccharide and conjugate vaccines to prevent otitis media. The proportion of otitis media caused by pneumococcal strains covered by the vaccines have decreased while those caused by Moraxella catarrhalis and nontypeable Haemophilus influenzae have significantly increased.

EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques

Enterovirus D68 (EV-D68) has been linked to the widespread outbreaks of respiratory illness and acute flaccid myelitis (AFM) in the United States and Europe in 2014, 2016, and 2018. Although EV-D68 is now the most frequently encountered enterovirus (41.1% of cases), with an estimated global prevalence of 4%, there are no specific, FDA-approved therapeutic interventions targeting this virus.

Anti-Nucleoprotein Crimean-Congo Hemorrhagic Fever Virus Monoclonal Antibodies for Assay Creation

Crimean-Congo hemorrhagic fever (CCHF) is the most widespread form of viral hemorrhagic fever, found in Eastern and Southern Europe, the Mediterranean, northwestern China, central Asia, Africa, the Middle East, and the Indian subcontinent. Typically beginning with non-specific fever, myalgia, nausea, diarrhea, and general malaise, symptoms of infection with the tick-borne CCHF virus (CCHFV) can rapidly progress to hemorrhagic manifestations, with case fatality rates as high as 30-40% in some regions.

Immortalized Rhesus macaque Bcl-6/Bcl-xL Stable B Cell Lines as Tools for HIV Antibody Discovery

Scientists at NIAID have developed two immortalized stable B cell lines from rhesus macaques that can have value as research tools for the discovery of neutralizing antibodies of simian origin against HIV and that may have value in the development of an HIV vaccine. These B cell lines encode human Bcl-6 and Bcl-xL proteins, which are major regulators of apoptosis. These B cell lines are derived from the lymph node of a rhesus macaque (RM) that was infected with SHIV.CH505.

Vesicular Stomatitis virus (VSV)-based Vaccine against Sudan Virus

There are five known Ebolavirus species: Ebola virus (Zaire ebolavirus); Sudan virus (Sudan ebolavirus or SUDV); Taï Forest virus (Taï Forest ebolavirus, formerly Cote d'Ivoire ebolavirus); Bundibugyo virus (Bundibugyo ebolavirus); and Reston virus (Reston ebolavirus). Last year an ebolavirus outbreak resulted in 164 cases and 55 deaths. While there is an FDA-approved Ebola virus vaccine authorized for use against Ebola virus infections, ERVEBO, this vaccine is not effective against SUDV due to the significant variation between Ebola virus and SUDV.

Antibodies and Methods for the Diagnosis and Treatment of Epstein-Barr Virus Infection

According to the World Health Organization, over 90% of the worldwide population is infected with Epstein-Barr virus by adulthood. In most cases, the disease accompanying initial infection is subclinical though some individuals who are infected as adolescents or adults do experience infectious mononucleosis. However, once infected, individuals carry latent EBV for their remaining lifespan. In such individuals, immune suppression can result in reactivation of the EBV and consequently, EBV-associated lymphoproliferative disease.

Enhanced Immune Response With Stabilized Norovirus VLPs: A Next-Generation Vaccine Approach

This technology includes a novel advancement in developing vaccines targeting norovirus, tailored specifically for a more robust and effective response. It centers around an improved version of Virus-Like Particles (VLPs) uniquely engineered for greater stability and efficacy. These enhanced VLPs are designed to remain intact even when faced with the body's immune responses, overcoming a key limitation of previous vaccine designs.

Subscribe to NIAID